Compare Gilead Sciences, Inc. (GILD) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Ferrari NV — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Ferrari NV trades at $389.91 (market cap $67.35B). The key difference: Gilead Sciences, Inc. is far larger — about 2.7× Ferrari NV's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Ferrari NV for 126 Days on average.
| GILD | RACE | |
|---|---|---|
Market Cap | $182.40B | $67.35B |
Volume | 4,469,821 | 390,618 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $436.54 |
52-Week Low | $116.74 | $314.63 |
Typical Hold Time | 111 Days | 126 Days |
Enterprise Value | $205.46B | $69.22B |
Dividend Yield | 2.23% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
Ferrari (RACE) trades at $389.91, up 0.91% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $7.15B and $1.60B in 2025, respectively. The company maintains high profitability margins and a robust balance sheet, though cash flow trends show recent volatility. Recent news highlights a share buyback program and strategic partnerships, supporting investor confidence.
The outlook for Ferrari remains positive due to consistent earnings beats, high margins, and analyst optimism, with a consensus price target of $462.75 implying 18.7% upside. Risks include valuation multiples above industry averages, competitive pressures in the luxury automotive sector, and macroeconomic sensitivity. Institutional buying activity and a dominant buy rating from analysts underscore long-term growth potential, but investors should monitor execution on future earnings and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
